Abbott has announced the integration of its Precision Oncology portfolio into Flatiron Health’s cloud-based electronic medical record (EMR) platform, OncoEMR.
The integration enables oncology providers to order Abbott tests digitally, monitor progress, and access results within their existing clinical workflow on OncoEMR.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Oncology clinicians can access Abbott tests such as Oncodetect, OncoExTra, Oncotype DX Breast Recurrence Score, and Riskguard through a single interface.
Providers may order tests individually or in combination and receive status updates.
This integration is designed to support treatment decisions at multiple stages of cancer care while helping to reduce administrative tasks for clinicians.
The collaboration will make Abbott’s Precision Oncology tests available throughout Flatiron’s network of more than 1,600 community cancer care centres in the US.
Flatiron vice-president and health point-of-care solutions general manager Quincy Weatherspoon said: “We’re focused on making it easier for clinicians to access the right information at the right moment of care.
“By integrating Abbott’s Precision Oncology portfolio directly into OncoEMR, we’re reducing friction in the workflow and helping providers move faster – from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care.”
Abbott Precision Oncology vice-president Brian Baranick said: “For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalised patient care.”
Earlier this month, Abbott announced results from the FreeDM2 randomised controlled trial, indicating that improved glucose outcomes were observed in individuals using the FreeStyle Libre continuous glucose monitoring technology for type 2 diabetes.
